Nathan Standifer

Feb 24, 2024 | nature.com | Adina M. Hughes |Nathan Standifer |Scott Hoffmann |Larissa S. Carnevalli |Fernando J. Calero-Nieto |Andrew Pierce | +9 more

AbstractThe Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8+ T-cell dependent antitumor activity, which is separate from the effects on tumor cells.

Feb 24, 2024 | nature.com | Adina M. Hughes |Nathan Standifer |Scott Hoffmann |Larissa S. Carnevalli |Fernando J. Calero-Nieto |Andrew Pierce | +9 more

AbstractThe Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8+ T-cell dependent antitumor activity, which is separate from the effects on tumor cells.